Streetbeat News

Revenues

CCCC

C4 Therapeutics (NASDAQ:CCCC) received mixed analyst ratings with a recent shift towards a more positive outlook, as evidenced by updated price targets and ratings from analysts at Wells Fargo, Stifel, and Morgan Stanley. The average 12-month price target for CCCC has been raised to $10.75, indicating a 30.3% increase from the previous target. This change reflects analysts' adapting recommendations based on market conditions and C4 Therapeutics' performance, including its financials showing revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 6:01 pm

NRDY

In the last three months, Nerdy (NYSE:NRDY) received mixed analyst ratings, with a shift towards a more positive outlook in recent evaluations. The average 12-month price target for NRDY has been raised to $4.19 from $3.25, indicating a 28.92% increase. Analysts from Goldman Sachs, Needham, and JP Morgan have updated their ratings and price targets, reflecting changes in market conditions and Nerdy's performance. Despite a lower market capitalization and challenges in profitability, Nerdy has shown impressive revenue growth of 31.77% as of December 31, 2023, surpassing industry averages in the Consumer Discretionary sector.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 6:01 pm

CXW

Recent analyst ratings for CoreCivic (NYSE:CXW) show a unanimous somewhat bullish outlook, with four analysts maintaining an 'Outperform' rating. The 12-month price target has been raised to an average of $18.75, indicating a 7.14% increase from the previous target of $17.50. CoreCivic's financial performance shows a revenue growth of 4.2% for the last quarter of 2023, but it trails behind industry averages in net margin, ROE, and ROA, indicating potential challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 6:00 pm

GXO

GXO Logistics (NYSE:GXO) has been the subject of 7 analyst ratings over the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target has been adjusted to $70.00, a decrease from the previous $73.33. Analyst actions include both upgrades and downgrades, with price targets ranging from $50.00 to $82.00. GXO's financial performance is strong, with revenue growth, net margin, ROE, and ROA all surpassing industry benchmarks. The company's market capitalization is below industry standards, but it maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 6:00 pm

AMZN

CMCSA

DIS

WBD

Warner Bros. Discovery Inc (NASDAQ:WBD) CEO David Zaslav is optimistic about retaining NBA rights against rivals like Comcast Corp's NBCUniversal and Amazon.com Inc's Prime Video. The competition could lead to higher fees for fewer NBA games for Warner and Disney. Zaslav believes in the appeal of Warner's sports lineup, including NCAA, NHL, and Nascar, despite potential financial challenges.

Portfolio Pulse from Shivani Kumaresan

May 09, 2024 | 5:56 pm

CRON

Cronos Group Inc. (NASDAQ:CRON) reported a 30% increase in net revenue for Q1 2024, reaching $25.3 million, primarily driven by sales in Canada and Israel. The company reduced its net loss to $2.48 million from $18.04 million in the same period last year. Gross profits rose by 53% to $4.48 million, and adjusted EBITDA losses decreased to $10.67 million. Cronos also reported $855 million in cash and equivalents, indicating strong financial positioning for future market expansion.

Portfolio Pulse from Nicolás Jose Rodriguez

May 09, 2024 | 5:18 pm

TOST

Over the last three months, 20 analysts have provided diverse opinions on Toast (NYSE:TOST), with recent updates showing a shift towards more positive ratings and higher price targets. The average 12-month price target has risen to $24.15, up 21.91% from the previous $19.81. Analysts from firms like Mizuho, Piper Sandler, and Goldman Sachs have adjusted their ratings and price targets, reflecting evolving market conditions and Toast's performance. Toast, a restaurant technology company, has shown notable revenue growth and processes a significant volume of transactions, despite its challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 5:01 pm

OSCR

Recent analyst evaluations of Oscar Health (NYSE:OSCR) show a mix of opinions, with 3 somewhat bullish and 1 indifferent rating in the last 30 days. The average 12-month price target for OSCR has been raised to $21.25, reflecting a 32.81% increase from the previous target of $16.00. Analysts from Wells Fargo, Goldman Sachs, and Raymond James have adjusted their ratings and price targets, indicating a positive outlook on the company's performance. Oscar Health's financials reveal a strong revenue growth rate of 45.8%, an impressive ROE of 19.32%, and an ROA of 4.42%, despite a net margin below industry averages and a smaller market capitalization.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 5:01 pm

HAIN

Hain Celestial Group (NASDAQ:HAIN) received mixed analyst ratings, with a shift towards a more cautious outlook. The average 12-month price target is now $9.83, down 19.43% from $12.20, reflecting lowered expectations. Analysts from firms like Maxim Group and Piper Sandler adjusted their ratings and price targets, indicating a response to Hain's market performance and financial challenges such as declining revenue and profitability metrics.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 5:00 pm

FXI

KBA

KWEB

MCHI

SPY

China's stock market has rebounded impressively after a sharp decline in January 2024, with key ETFs like KWEB, KBA, MCHI, and FXI outperforming major U.S. equity ETFs such as SPY. KraneShares CIO Brendan Ahern cites government support, changing global investor sentiments, policy reforms, economic recovery, and attractive valuations as drivers for this resurgence, suggesting a promising outlook for Chinese equities.

Portfolio Pulse from Surbhi Jain

May 09, 2024 | 4:50 pm